Close Menu

Philips

The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.

The Philips platform will support oncology testing workflows and helped with the launch of Illumina TruSight Tumor 170 NGS testing at the Florida institute.

As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.

Philips and its partners aim to combine liquid biopsy with magnetic resonance imaging to enable personalized cancer treatment.

Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.

The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.